Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

Research

Duration of protection after first dose of acellular pertussis vaccine in infants

Without a booster dose, the effectiveness of 3 doses waned more rapidly from 2 to 4 years of age than previously documented for children >6 years of age who...

Research

The challenge of enteric fever

Enteric fever prevention requires significant long term investment in provision of clean water and sanitation; vaccination offers medium term control.

People

Dr Ruth Thornton

Co-head, Bacterial Respiratory Infectious Disease Group (BRIDG)

Research

Towards the establishment of the PREVAIL Centre, a Centre for PREcision in VAccine ImpLmentation at The Kids Research Institute Australia

Pat Tom Holt Snelling PhD, DSc, FRCPath, FRCPI, FAA BMBS DTMH GDipClinEpid PhD FRACP Emeritus Honorary Researcher Head, Infectious Disease

Research

Informing rubella vaccination strategies in East Java, Indonesia through transmission modelling

A single dose of rubella vaccine will take longer to reduce the burden of rubella and will be less robust to lower vaccine coverage

Research

Vaccine hesitancy, refusal and access barriers: The need for clarity in terminology

We propose more precision in the term 'vaccine hesitancy' is needed particularly since much under-vaccination arises from factors related to access or pragmatics

Research

Nurses are underutilised in antimicrobial stewardship - Results of a multisite survey in paediatric and adult hospitals

Nurses consider antimicrobial stewardship activities within their roles, but are underutilised in antimicrobial stewardship programs

Research

Comprehending the Health Informatics Spectrum: Grappling with System Entropy and Advancing Quality Clinical Research

We outline three scenarios from across the health spectrum where issues with health informatics are exemplified.

Research

Effectiveness of Palivizumab in Preventing RSV Hospitalization in High Risk Children: A Real-World Perspective

This review supports the recommended use of palivizumab for reducing RSV-associated hospitalisation rates in premature babies born at gestational age <33 weeks.

Research

Impact of high coverage of monovalent human rotavirus vaccine on Emergency Department presentations for rotavirus gastroenteritis

The program was associated with a substantial decline in rotavirus attributable non-admitted AGE presentations to ED among children aged <5 years.